Sugi Predict

Sugi Predict / Compounds / SCHEMBL6803523

SCHEMBL6803523

SCHEMBL6803523

NC(=O)c1ccc(N2CCC(C(c3ccccc3)c3ccccc3)CC2)c(NC(=O)Nc2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ LMNA P02545 5/20 0.48
▸ TP53 P04637 2/20 0.48
▸ NPY2R P49146 3/20 0.44
▸ MTTP P55157 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ HPGD P15428 4/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ KCNQ2 O43526 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ PLAU P00749 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HTR1E P28566 1/20 0.40
▸ S1PR3 Q99500 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29968697 1.00 MAPT (0.49) MAPTKDM4ELMNATP53NPY2R
SCHEMBL6797486 0.84 PARP14 (0.50) MAPTKDM4ELMNATP53GAA
SCHEMBL29968508 0.84 PARP14 (0.50) MAPTKDM4ELMNATP53GAA
SCHEMBL29968131 0.83 MAPT (0.51) MAPTKDM4ELMNATP53NPY2R
SCHEMBL6686127 0.83 MAPT (0.51) MAPTKDM4ELMNATP53NPY2R
SCHEMBL6799649 0.82 CCR3 (0.55) MAPTKDM4ELMNATP53GAA
SCHEMBL29968547 0.82 CCR3 (0.55) MAPTKDM4ELMNATP53GAA
SCHEMBL3660952 0.79 HPGD (0.50) MAPTLMNATP53NPY2RMTTP
SCHEMBL6792633 0.78 LMNA (0.51) MAPTKDM4ELMNATP53GAA
SCHEMBL29968476 0.78 LMNA (0.51) MAPTKDM4ELMNATP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242639-A1 Phospholipase C inhibitors for use in treating inflammatory disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-12-02 — — US claimed
WO-2004089901-A2 PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2004-10-21 — — WO claimed
US-20250017878-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LTD (AU) 2025-01-16 — — US disclosed
CN-117999073-A Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway 慢性呼吸道治疗有限公司 2024-05-07 — — CN disclosed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017878-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY ARRB1, ADRB2, ADRB1 MAPT 1043/4885KDM4E 4702/4885LMNA 2136/4885
US-20040242639-A1 Phospholipase C inhibitors for use in treating inflammatory disorders PLA2G4C, PLA2G4B, PLA2G5 MAPT 4701/4885KDM4E 3920/4885LMNA 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.